A research team made a pivotal discovery in the field of cancer immunotherapy. The team identified a specific population of immune cells that play a critical role in successful treatment of relapsed ...

A research team from Columbia Engineering and the Irving Institute for Cancer Dynamics made a pivotal discovery in the field ...

Researchers have identified key factors that determine the success of leukemia cell therapies, including DLI, in achieving ...

Galinpepimut-S therapy showed specific T-Cell immune responses for patients with acute myeloid leukemia in remission ...

Columbia Engineering and Irving Institute researchers unveil a significant finding in cancer immunotherapy, uncovering unique ...

Dana-Farber Cancer Institute researchers have identified factors that determine whether donor lymphocyte infusion (DLI), a ...

"Relapse of AML after stem cell transplant is a major ... Further, exactly how the cells in the DLI product help move leukemia into remission are not known, making it difficult for investigators ...

Dana-Farber Cancer Institute researchers have identified factors that determine whether donor lymphocyte infusion (DLI), a standard therapy for patients with acute myeloid leukemia (AML) who have ...

Relapse of AML after stem cell transplant is a major ... Further, exactly how the cells in the DLI product help move leukemia into remission are not known, making it difficult for investigators ...

The phase 3 REGAL trial of galinpepimut-S in acute myeloid leukemia can proceed without modifications, based on findings from ...